Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 606,081
  • Shares Outstanding, K 52,520
  • Annual Sales, $ 1,044 M
  • Annual Income, $ -190,600 K
  • EBIT $ 184 M
  • EBITDA $ 300 M
  • 60-Month Beta 2.35
  • Price/Sales 0.86
  • Price/Cash Flow 6.10
  • Price/Book 1.06

Options Overview Details

View History
  • Implied Volatility 117.93% (-49.01%)
  • Historical Volatility 58.74%
  • IV Percentile 61%
  • IV Rank 14.68%
  • IV High 509.14% on 04/04/25
  • IV Low 50.62% on 01/16/26
  • Expected Move (DTE 16) 1.21 (10.58%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 64
  • Volume Avg (30-Day) 507
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 11,787
  • Open Int (30-Day) 12,679
  • Expected Range 10.20 to 12.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.05
  • Growth Rate Est. (year over year) +1,997,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.60 +7.64%
on 01/20/26
14.06 -18.85%
on 01/07/26
-1.10 (-8.79%)
since 01/02/26
3-Month
9.02 +26.50%
on 11/21/25
14.06 -18.85%
on 01/07/26
+1.32 (+13.08%)
since 11/04/25
52-Week
4.02 +183.83%
on 04/09/25
14.06 -18.85%
on 01/07/26
+0.72 (+6.74%)
since 02/04/25

Most Recent Stories

More News
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness

Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying...

EBS : 11.41 (-1.13%)
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in...

EBS : 11.41 (-1.13%)
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to...

EBS : 11.41 (-1.13%)
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide additional...

EBS : 11.41 (-1.13%)
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

GAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during...

EBS : 11.41 (-1.13%)
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License...

EBS : 11.41 (-1.13%)
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN ® (naloxone...

EBS : 11.41 (-1.13%)
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November...

EBS : 11.41 (-1.13%)
Emergent Biosolutions: Q3 Earnings Snapshot

Emergent Biosolutions: Q3 Earnings Snapshot

EBS : 11.41 (-1.13%)
Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025...

EBS : 11.41 (-1.13%)

Business Summary

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside...

See More

Key Turning Points

3rd Resistance Point 12.22
2nd Resistance Point 12.01
1st Resistance Point 11.71
Last Price 11.41
1st Support Level 11.20
2nd Support Level 10.99
3rd Support Level 10.69

See More

52-Week High 14.06
Last Price 11.41
Fibonacci 61.8% 10.22
Fibonacci 50% 9.04
Fibonacci 38.2% 7.86
52-Week Low 4.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar